South San Francisco-based biotech firm VistaGen Therapeutics raised $1 million in grant funding from the California Institute for Regenerative Medicine (CIRM) to distribute to researchers and other companies working on stem-cell projects linked to diabetes and neurological disorders, reports VentureWire.
VistaGen has raised about $18 million to date, reports VentureWire -- including a $3.75 million bridge round snapped up in August. At the time, it dropped the possibility of seeking a $20 million fourth round of funding.